Clinical Trial Update: Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 MyeloMATCH trial evaluating adding venetoclax or gemtuzumab ozogamicin to the 7+3 regimen for core-binding factor acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Core-binding Factor Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Venetoclax (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Core Binding Factor Acute Myeloid Leukemia | Phase 2 | Status: NOT_YET_RECRUITING